Letrozole

Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].

Product Specifications

CAS Number

[112809-51-5]

Product Name Alternative

CGS 20267

UNSPSC

12352005

Hazard Statement

H361, H373

Target

Autophagy; Cytochrome P450

Type

Natural Products

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Letrozole.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C(C(N2C=NC=N2)C3=CC=C(C#N)C=C3)C=C1

Molecular Formula

C17H11N5

Molecular Weight

285.30

Precautions

H361, H373

References & Citations

[1]Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37 (6) :1021-7.|[2]Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104 (2) :155-60.|[3]Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44 (4-6) :633-6.